Trial Profile
RELIf-CHF: Longterm treatment with ivabradine in ambulatory patients with chronic systolic heart failure - a prospective non-interventional study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Jun 2015
Price :
$35
*
At a glance
- Drugs Ivabradine (Primary)
- Indications Chronic heart failure
- Focus Adverse reactions; Therapeutic Use
- Acronyms RELIf-CHF
- Sponsors Servier
- 29 Apr 2015 Status changed from recruiting to completed as per ISRCTN: Current Controlled Trials record..
- 02 May 2014 New trial record